Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Inclusion Criteria: * Histologically confirmed solid tumor refractory to conventional treatment or whom no standard of treatment exists * Life expectancy of \> 12 weeks * World Health Organization (WHO) performance status of \< 2 Exclusion Criteria: * Known severe hypersensitivity to gefitinib or any of the excipients of this product * Less than 4 weeks since completion of prior chemotherapy or radiation therapy (except nitrosoureas or mitomycin-C which must have a wash out period of 6 weeks) * Incomplete healing from previous oncologic or other major surgery